Search - tctmd.com

Displaying 301 - 320 of 610

Sort: Relevancy | Date

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Opinion Off Script TCT 2017

Off Script: Welcome to TCT 2017 in the Mile High City

Kwan S. Lee

October 29, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Featured Fellow

Felipe Albuquerque, MD

Yael L. Maxwell

September 28, 2017

News Daily News

‘J-Curve’ in Hypertension May Be Explained by Differences in Patient Characteristics

Todd Neale

September 26, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

Studies Supporting Device Modifications Weak, Often Based on Surrogate Endpoints

News Daily News

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Michael O'Riordan

August 16, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Higher Burden of Medicaid and Uninsured Patients Means Hospitals Less Likely to Rescue After Trouble in Abdominal Aortic Surgery

News Daily News

More ‘Safety-Net’ Patients, Fewer Saves When Abdominal Aorta Surgery Goes Awry

Ashley Lyles

July 27, 2017

News Opinion Fellow Talk

On Mentoring: A Brain to Pick, an Ear to Listen, and a Push in the Right Direction

Kimberly Atianzar, MD

July 18, 2017

News Opinion Fellow Talk

2017-2018 Fellow Talk Bloggers

July 18, 2017

News Featured Fellow

Nirmanmoh Bhatia, MD

Yael L. Maxwell

July 11, 2017

News Daily News

Incidental Findings on CT Angiography Predict All-Cause Mortality Following TAVR

Alison Palkhivala

July 07, 2017

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Featured Fellow

Ankur Kalra, MD

Yael L. Maxwell

May 26, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

Visits Nixed: Efforts to Limit Pharma Reps’ Influence Seem to Bear Fruit

Caitlin E. Cox

May 02, 2017

Advertisement

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Off Script: Welcome to TCT 2017 in the Mile High City

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Felipe Albuquerque, MD

‘J-Curve’ in Hypertension May Be Explained by Differences in Patient Characteristics

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

More ‘Safety-Net’ Patients, Fewer Saves When Abdominal Aorta Surgery Goes Awry

On Mentoring: A Brain to Pick, an Ear to Listen, and a Push in the Right Direction

2017-2018 Fellow Talk Bloggers

Nirmanmoh Bhatia, MD

Incidental Findings on CT Angiography Predict All-Cause Mortality Following TAVR

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Ankur Kalra, MD

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Visits Nixed: Efforts to Limit Pharma Reps’ Influence Seem to Bear Fruit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content